US2005137144A1PendingUtilityA1

Method for treating obesity

55
Priority: May 17, 2002Filed: Feb 15, 2005Published: Jun 23, 2005
Est. expiryMay 17, 2022(expired)· nominal 20-yr term from priority
Inventors:Kishore M. GaddeK. Ranga R. Krishnan
A61P 9/12A61P 3/10A61P 43/00A61P 3/06A61K 31/42A61P 31/04A61K 31/357A61K 31/137A61K 31/35A61K 31/7024A61K 45/06A61P 3/04A61K 31/255A61K 31/423
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claims

exact text as granted — not AI-modified
1 - 17 . (canceled)  
     
     
         18 . A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one weight-loss promoting anticonvulsant selected from the group consisting of zonisamide and topiramate, and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said treatment is effected.  
     
     
         19 . The method of  claim 18  wherein said anticonvulsant is zonisamide.  
     
     
         20 . The method of  claim 18  wherein said compound that enhances the activity of norepinephrine and/or dopamine is selected from the group consisting of bupropion, atomoxetine, and reboxetine.  
     
     
         21 . The method of  claim 18  wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.  
     
     
         22 . The method of  claim 18  wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.  
     
     
         23 . The method of  claim 18  wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.  
     
     
         24 . A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such treatment at least one weight-loss promoting anticonvulsant selected from the group consisting of zonisamide and topiramate, and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said reduction is effected.  
     
     
         25 . The method of  claim 24  wherein said anticonvulsant is zonisamide.  
     
     
         26 . The method of  claim 24  wherein said compound that enhances the activity of norepinephrine and/or dopamine is selected from the group consisting of bupropion, atomoxetine, and reboxetine.  
     
     
         27 . The method of  claim 24  wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.  
     
     
         28 . A composition comprising at least one weight-loss promoting anticonvulsant selected from the group consisting of zonisamide and topiramate, and at least one compound that enhances the activity of norepinephrine and/or dopamine.  
     
     
         29 . The composition of  claim 24  wherein said anticonvulsant is zonisamide.  
     
     
         30 . The composition of  claim 24  wherein said compound that enhances the activity of norepinephrine and/or dopamine is selected from the group consisting of bupropion, atomoxetine, and reboxetine.  
     
     
         31 . The composition of  claim 24  wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.  
     
     
         32 . The composition of  claim 24  wherein said compound is in dosage unit form.  
     
     
         33 . The composition of  claim 24  wherein said composition is in the form of a tablet or capsule.  
     
     
         34 . The composition of  claim 24  wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion and said anticonvulsant is zonisamide.

Join the waitlist — get patent alerts

Track US2005137144A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.